1. Home
  2. TAOP vs CDT Comparison

TAOP vs CDT Comparison

Compare TAOP & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TAOP

Taoping Inc.

HOLD

Current Price

$2.33

Market Cap

2.9M

Sector

Technology

ML Signal

HOLD

Logo Conduit Pharmaceuticals Inc.

CDT

Conduit Pharmaceuticals Inc.

HOLD

Current Price

$1.97

Market Cap

3.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TAOP
CDT
Founded
1993
2019
Country
China
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9M
3.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
TAOP
CDT
Price
$2.33
$1.97
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
1.1M
400.8K
Earning Date
12-08-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$36,196,786.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.81
$1.48
52 Week High
$24.75
$2,198.40

Technical Indicators

Market Signals
Indicator
TAOP
CDT
Relative Strength Index (RSI) 50.62 48.79
Support Level $2.03 $1.69
Resistance Level $2.84 $2.03
Average True Range (ATR) 0.31 0.25
MACD 0.05 0.01
Stochastic Oscillator 43.41 56.48

Price Performance

Historical Comparison
TAOP
CDT

About TAOP Taoping Inc.

Taoping Inc is a provider of cloud-app technologies for smart city IoT platforms, digital advertising delivery, and other internet-based information distribution systems in China. Its operating segment includes Cloud-based Technology (CBT), Blockchain Technology (BT), and Traditional Information Technology (TIT). It generates maximum revenue from the CBT segment. CBT segment includes cloud-based products and services offered to customers in the private sector including new media, healthcare, education, and residential community management.

About CDT Conduit Pharmaceuticals Inc.

CDT Equity Inc, formerly Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

Share on Social Networks: